<p>Relay Therapeutics（納斯達克代碼：RLAY - 獲取免費報告）在週三發佈的報告中，Citizens Jmp 的股票分析師將其目標價格從 19.00 美元上調至 21.00 美元，Benzinga 報道。該公司目前對該股票的評級為 “市場表現優於大盤”。Citizens Jmp 的目標價格暗示該股票相較於之前的收盤價有 73.99% 的潛在上漲空間。</p>
<p>獲取 <strong>Relay Therapeutics</strong> 的提醒：</p>
<ul>
<li>解鎖醫療保健領域的人工智能投資機會</li>
</ul>
<p>其他股票分析師最近也對該公司發佈了報告。瑞銀集團在週二的研究報告中將 Relay Therapeutics 的目標價格設定為 26.00 美元。花旗集團在週三的研究報告中重申了對 Relay Therapeutics 股票的 “跑贏大盤” 評級。HC Wainwright 在 4 月 29 日的研究報告中將 Relay Therapeutics 的目標價格從 19.00 美元上調至 25.00 美元，並給予該公司 “買入” 評級。富國銀行在 4 月 28 日的研究報告中將 Relay Therapeutics 的目標價格從 17.00 美元上調至 21.00 美元，並給予該股票 “增持” 評級。最後，Raymond James Financial 在週二的報告中重申了對 Relay Therapeutics 股票的 “強力買入” 評級。一位股票研究分析師對該股票給予了 “強力買入” 評級，八位分析師給予 “買入” 評級，一位分析師給予 “持有” 評級，一位分析師給予 “賣出” 評級。根據 MarketBeat 的數據，該股票目前的共識評級為 “適度買入”，平均目標價格為 22.60 美元。</p>
<p><strong>閲讀我們關於 RLAY 的最新研究報告</strong></p>
<h2>Relay Therapeutics 股票下跌 0.2%</h2>
<p>週三，RLAY 股票開盤價為 12.07 美元。該公司的 50 日移動平均線為 12.56 美元，200 日移動平均線為 9.62 美元。該股票的市值為 23.1 億美元，市盈率為-7.69，貝塔值為 1.74。Relay Therapeutics 的 52 周低點為 2.75 美元，52 周高點為 17.32 美元。</p>
<p>Relay Therapeutics（納斯達克代碼：RLAY - 獲取免費報告）在 5 月 5 日（週二）發佈了季度財報。該公司報告每股收益（EPS）為-0.41 美元，低於分析師的共識預期（-0.35 美元）0.06 美元。該季度的營業收入為 300 萬美元，而分析師預期為 558 萬美元。平均而言，股票研究分析師預計 Relay Therapeutics 在當前年度的每股收益為-1.6 美元。</p>
<h2>Relay Therapeutics 的內部交易</h2>
<p>在其他 Relay Therapeutics 的新聞中，首席財務官 Thomas Catinazzo 在 5 月 14 日（週四）出售了 17,717 股公司的股票。股票以平均價格 12.86 美元出售，總價值為 227,840.62 美元。出售後，首席財務官直接持有 195,178 股公司的股票，價值約為 2,509,989.08 美元。這代表了他們持股比例的 8.32% 的減少。該交易已在提交給證券交易委員會的文件中披露，可以通過此鏈接訪問。在過去三個月中，內部人士已出售價值 532,889 美元的 40,449 股公司股票。內部人士持有公司股票的 5.04%。</p>
<h2>Relay Therapeutics 的機構交易</h2>
<p>對該股票的對沖基金最近修改了持股情況。Sanctuary Advisors LLC 在第一季度將其在 Relay Therapeutics 的持股增加了 1.1%。Sanctuary Advisors LLC 現在擁有 143,816 股公司股票，價值 1,431,000 美元，此前在該期間內又購買了 1,588 股。Mirae Asset Global Investments Co. Ltd.在第四季度將其在 Relay Therapeutics 的持股增加了 26.4%。Mirae Asset Global Investments Co. Ltd.現在擁有 8,422 股公司股票，價值 71,000 美元，此前在上個季度又購買了 1,757 股。Abel Hall LLC 在第四季度將其在 Relay Therapeutics 的持股增加了 16.2%。Abel Hall LLC 現在擁有 12,984 股公司股票，價值 110,000 美元，此前在上個季度又購買了 1,809 股。Cresset Asset Management LLC 在第三季度將其在 Relay Therapeutics 的持股增加了 5.0%。Cresset Asset Management LLC 現在擁有 38,932 股公司股票，價值 203,000 美元，此前在該期間內又購買了 1,848 股。最後，Vanguard Personalized Indexing Management LLC 在第三季度將其在 Relay Therapeutics 的持股增加了 8.1%。Vanguard Personalized Indexing Management LLC 現在擁有 27,871 股公司股票，價值 145,000 美元，此前在該期間內又購買了 2,079 股。對沖基金和其他機構投資者持有公司股票的 96.98%。</p>
<h2>Relay Therapeutics 新聞摘要</h2>
<p>以下是本週影響 Relay Therapeutics 的主要新聞：</p>
<ul>
<li>積極情緒：Relay Therapeutics 的 zovegalisib 在血管異常方面顯示出良好的早期療效和耐受性，增強了其更廣泛商業機會的案例。文章：Relay Therapeutics 宣佈初步臨牀數據，表明 zovegalisib 在 PIK3CA 驅動的血管異常患者中具有差異化的安全性和療效潛力</li>
<li>積極情緒：Raymond James 將 RLAY 的目標價格上調至 26 美元，並重申強力買入觀點，反映出對管線的樂觀情緒。文章：Relay Therapeutics 的目標價格被 Raymond James 上調</li>
<li>中性情緒：該公司表示其現金儲備充足，能夠持續到 2029 年，這減少了近期融資的擔憂，但這在很大程度上被宣佈的 1.75 億美元股票發行所抵消。文章：Relay Therapeutics 宣佈擬公開發行普通股</li>
<li>消極情緒：Relay 推出了擬公開發行普通股的計劃，這可能會稀釋現有股東的股份，並在短期內對股票施加壓力。文章：Relay Therapeutics 宣佈擬公開發行普通股</li>
</ul>
<h2>關於 Relay Therapeutics</h2>
<p>（獲取免費報告）</p>
<p>Relay Therapeutics, Inc 是一家臨牀階段的生物技術公司，專注於腫瘤學的精準治療的發現和開發。公司總部位於馬薩諸塞州劍橋，成立於 2016 年，旨在利用綜合科學平台針對動態蛋白質運動。Relay Therapeutics 利用計算建模、結構生物學和實驗驗證來識別能夠調節與疾病相關的蛋白質行為的小分子藥物候選者。</p>
<p>公司的核心業務活動集中在其專有的藥物發現引擎上，該引擎結合了高性能計算——包括分子動力學模擬——與先進的實驗技術，如冷凍電子顯微鏡和生物物理篩選。</p>
<h2>精選故事</h2>
<ul>
<li>五隻我們認為比 Relay Therapeutics 更好的股票</li>
<li>Strategy Inc.購買比特幣並在市場恐慌中尋求分紅</li>
<li>Vertical Aerospace：飛行前檢查指向突破</li>
<li>Palo Alto Networks 上漲 70%：這波反彈能持續到 6 月嗎？</li>
<li>Block 向利潤和人工智能的轉型引起關注</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkxBWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkxBWQ"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資$1,000 在 Relay Therapeutics 嗎？</h2>
<p>在考慮 Relay Therapeutics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Relay Therapeutics 並不在名單上。</p>
<p>雖然 Relay Therapeutics 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

RLAY

動態生物技術與基因組 ETF - Invesco

醫藥突破 ETF - ALPS

<p>Citizens Jmp 將 Relay Therapeutics (NASDAQ: RLAY) 的目標價格從 19.00 美元上調至 21.00 美元，維持 “市場表現優於大盤” 的評級。這表明與前一交易日收盤價相比，潛在上漲幅度為 73.99%。其他分析師也設定了 21.00 美元至 26.00 美元的目標，整體評級為 “適度買入”，平均目標價格為 22.60 美元</p>

<p>Relay Therapeutics (NASDAQ:RLAY - Get Free Report) had its price objective raised by stock analysts at Citizens Jmp from $19.00 to $21.00 in a report issued on Wednesday,Benzinga reports. The firm currently has a &#34;market outperform&#34; rating on the stock. Citizens Jmp's price target would suggest a potential upside of 73.99% from the stock's previous close.</p>
<div class="lb-trans"><p>Relay Therapeutics（納斯達克代碼：RLAY - 獲取免費報告）在週三發佈的報告中，Citizens Jmp 的股票分析師將其目標價格從 19.00 美元上調至 21.00 美元，Benzinga 報道。該公司目前對該股票的評級為 “市場表現優於大盤”。Citizens Jmp 的目標價格暗示該股票相較於之前的收盤價有 73.99% 的潛在上漲空間。</p>
</div><p>Get <strong>Relay Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Relay Therapeutics</strong> 的提醒：</p>
</div><ul>
<li>Unlocking AI investment opportunities in healthcare</li>
</ul>
<div class="lb-trans"><ul>
<li>解鎖醫療保健領域的人工智能投資機會</li>
</ul>
</div><p>Other equities analysts also recently issued reports about the company. UBS Group set a $26.00 target price on Relay Therapeutics in a research report on Tuesday. Citigroup reaffirmed an &#34;outperform&#34; rating on shares of Relay Therapeutics in a research report on Wednesday. HC Wainwright boosted their price target on Relay Therapeutics from $19.00 to $25.00 and gave the company a &#34;buy&#34; rating in a research note on Wednesday, April 29th. Wells Fargo &amp; Company raised their price objective on Relay Therapeutics from $17.00 to $21.00 and gave the stock an &#34;overweight&#34; rating in a research note on Tuesday, April 28th. Finally, Raymond James Financial reaffirmed a &#34;strong-buy&#34; rating on shares of Relay Therapeutics in a report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $22.60.</p>
<div class="lb-trans"><p>其他股票分析師最近也對該公司發佈了報告。瑞銀集團在週二的研究報告中將 Relay Therapeutics 的目標價格設定為 26.00 美元。花旗集團在週三的研究報告中重申了對 Relay Therapeutics 股票的 “跑贏大盤” 評級。HC Wainwright 在 4 月 29 日的研究報告中將 Relay Therapeutics 的目標價格從 19.00 美元上調至 25.00 美元，並給予該公司 “買入” 評級。富國銀行在 4 月 28 日的研究報告中將 Relay Therapeutics 的目標價格從 17.00 美元上調至 21.00 美元，並給予該股票 “增持” 評級。最後，Raymond James Financial 在週二的報告中重申了對 Relay Therapeutics 股票的 “強力買入” 評級。一位股票研究分析師對該股票給予了 “強力買入” 評級，八位分析師給予 “買入” 評級，一位分析師給予 “持有” 評級，一位分析師給予 “賣出” 評級。根據 MarketBeat 的數據，該股票目前的共識評級為 “適度買入”，平均目標價格為 22.60 美元。</p>
</div><p><strong>Read Our Latest Research Report on RLAY</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 RLAY 的最新研究報告</strong></p>
</div><h2>Relay Therapeutics Stock Down 0.2%</h2>
<div class="lb-trans"><h2>Relay Therapeutics 股票下跌 0.2%</h2>
</div><p>RLAY stock opened at $12.07 on Wednesday. The firm has a 50 day moving average of $12.56 and a 200 day moving average of $9.62. The stock has a market capitalization of $2.31 billion, a PE ratio of -7.69 and a beta of 1.74. Relay Therapeutics has a 52 week low of $2.75 and a 52 week high of $17.32.</p>
<div class="lb-trans"><p>週三，RLAY 股票開盤價為 12.07 美元。該公司的 50 日移動平均線為 12.56 美元，200 日移動平均線為 9.62 美元。該股票的市值為 23.1 億美元，市盈率為-7.69，貝塔值為 1.74。Relay Therapeutics 的 52 周低點為 2.75 美元，52 周高點為 17.32 美元。</p>
</div><p>Relay Therapeutics (NASDAQ:RLAY - Get Free Report) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.06). The business had revenue of $3.00 million for the quarter, compared to analyst estimates of $5.58 million. On average, equities research analysts expect that Relay Therapeutics will post -1.6 earnings per share for the current year.</p>
<div class="lb-trans"><p>Relay Therapeutics（納斯達克代碼：RLAY - 獲取免費報告）在 5 月 5 日（週二）發佈了季度財報。該公司報告每股收益（EPS）為-0.41 美元，低於分析師的共識預期（-0.35 美元）0.06 美元。該季度的營業收入為 300 萬美元，而分析師預期為 558 萬美元。平均而言，股票研究分析師預計 Relay Therapeutics 在當前年度的每股收益為-1.6 美元。</p>
</div><h2>Insider Transactions at Relay Therapeutics</h2>
<div class="lb-trans"><h2>Relay Therapeutics 的內部交易</h2>
</div><p>In other Relay Therapeutics news, CFO Thomas Catinazzo sold 17,717 shares of the company's stock in a transaction on Thursday, May 14th. The shares were sold at an average price of $12.86, for a total value of $227,840.62. Following the sale, the chief financial officer directly owned 195,178 shares of the company's stock, valued at approximately $2,509,989.08. This represents a 8.32% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through this link. Insiders have sold 40,449 shares of company stock worth $532,889 in the last three months. Insiders own 5.04% of the company's stock.</p>
<div class="lb-trans"><p>在其他 Relay Therapeutics 的新聞中，首席財務官 Thomas Catinazzo 在 5 月 14 日（週四）出售了 17,717 股公司的股票。股票以平均價格 12.86 美元出售，總價值為 227,840.62 美元。出售後，首席財務官直接持有 195,178 股公司的股票，價值約為 2,509,989.08 美元。這代表了他們持股比例的 8.32% 的減少。該交易已在提交給證券交易委員會的文件中披露，可以通過此鏈接訪問。在過去三個月中，內部人士已出售價值 532,889 美元的 40,449 股公司股票。內部人士持有公司股票的 5.04%。</p>
</div><h2>Institutional Trading of Relay Therapeutics</h2>
<div class="lb-trans"><h2>Relay Therapeutics 的機構交易</h2>
</div><p>Hedge funds have recently modified their holdings of the stock. Sanctuary Advisors LLC grew its holdings in Relay Therapeutics by 1.1% during the first quarter. Sanctuary Advisors LLC now owns 143,816 shares of the company's stock worth $1,431,000 after acquiring an additional 1,588 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its position in Relay Therapeutics by 26.4% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,422 shares of the company's stock worth $71,000 after purchasing an additional 1,757 shares in the last quarter. Abel Hall LLC boosted its position in Relay Therapeutics by 16.2% in the 4th quarter. Abel Hall LLC now owns 12,984 shares of the company's stock worth $110,000 after purchasing an additional 1,809 shares in the last quarter. Cresset Asset Management LLC grew its stake in shares of Relay Therapeutics by 5.0% during the 3rd quarter. Cresset Asset Management LLC now owns 38,932 shares of the company's stock worth $203,000 after purchasing an additional 1,848 shares during the period. Finally, Vanguard Personalized Indexing Management LLC grew its stake in shares of Relay Therapeutics by 8.1% during the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 27,871 shares of the company's stock worth $145,000 after purchasing an additional 2,079 shares during the period. Hedge funds and other institutional investors own 96.98% of the company's stock.</p>
<div class="lb-trans"><p>對該股票的對沖基金最近修改了持股情況。Sanctuary Advisors LLC 在第一季度將其在 Relay Therapeutics 的持股增加了 1.1%。Sanctuary Advisors LLC 現在擁有 143,816 股公司股票，價值 1,431,000 美元，此前在該期間內又購買了 1,588 股。Mirae Asset Global Investments Co. Ltd.在第四季度將其在 Relay Therapeutics 的持股增加了 26.4%。Mirae Asset Global Investments Co. Ltd.現在擁有 8,422 股公司股票，價值 71,000 美元，此前在上個季度又購買了 1,757 股。Abel Hall LLC 在第四季度將其在 Relay Therapeutics 的持股增加了 16.2%。Abel Hall LLC 現在擁有 12,984 股公司股票，價值 110,000 美元，此前在上個季度又購買了 1,809 股。Cresset Asset Management LLC 在第三季度將其在 Relay Therapeutics 的持股增加了 5.0%。Cresset Asset Management LLC 現在擁有 38,932 股公司股票，價值 203,000 美元，此前在該期間內又購買了 1,848 股。最後，Vanguard Personalized Indexing Management LLC 在第三季度將其在 Relay Therapeutics 的持股增加了 8.1%。Vanguard Personalized Indexing Management LLC 現在擁有 27,871 股公司股票，價值 145,000 美元，此前在該期間內又購買了 2,079 股。對沖基金和其他機構投資者持有公司股票的 96.98%。</p>
</div><h2>Relay Therapeutics News Summary</h2>
<div class="lb-trans"><h2>Relay Therapeutics 新聞摘要</h2>
</div><p>Here are the key news stories impacting Relay Therapeutics this week:</p>
<div class="lb-trans"><p>以下是本週影響 Relay Therapeutics 的主要新聞：</p>
</div><ul>
<li>Positive Sentiment: Relay Therapeutics’ zovegalisib showed promising early efficacy and tolerability in vascular anomalies, strengthening the case for a broader commercial opportunity. Article: Relay Therapeutics Announces Initial Clinical Data Demonstrating That Zovegalisib Has Potential for Differentiated Safety and Efficacy in Patients with PIK3CA-Driven Vascular Anomalies</li>
<li>Positive Sentiment: Raymond James raised its price target on RLAY to $26 and reiterated a strong-buy view, reflecting optimism around the pipeline. Article: Relay Therapeutics price target raised by Raymond James</li>
<li>Neutral Sentiment: The company said it has a sizable cash position and runway into 2029, which reduces near-term financing concerns, but this was largely offset by the announced $175 million stock offering. Article: Relay Therapeutics Announces Proposed Public Offering of Common Stock</li>
<li>Negative Sentiment: Relay launched a proposed public offering of common stock, which can dilute existing shareholders and pressure the stock in the near term. Article: Relay Therapeutics Announces Proposed Public Offering of Common Stock</li>
</ul>
<div class="lb-trans"><ul>
<li>積極情緒：Relay Therapeutics 的 zovegalisib 在血管異常方面顯示出良好的早期療效和耐受性，增強了其更廣泛商業機會的案例。文章：Relay Therapeutics 宣佈初步臨牀數據，表明 zovegalisib 在 PIK3CA 驅動的血管異常患者中具有差異化的安全性和療效潛力</li>
<li>積極情緒：Raymond James 將 RLAY 的目標價格上調至 26 美元，並重申強力買入觀點，反映出對管線的樂觀情緒。文章：Relay Therapeutics 的目標價格被 Raymond James 上調</li>
<li>中性情緒：該公司表示其現金儲備充足，能夠持續到 2029 年，這減少了近期融資的擔憂，但這在很大程度上被宣佈的 1.75 億美元股票發行所抵消。文章：Relay Therapeutics 宣佈擬公開發行普通股</li>
<li>消極情緒：Relay 推出了擬公開發行普通股的計劃，這可能會稀釋現有股東的股份，並在短期內對股票施加壓力。文章：Relay Therapeutics 宣佈擬公開發行普通股</li>
</ul>
</div><h2>About Relay Therapeutics</h2>
<div class="lb-trans"><h2>關於 Relay Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.</p>
<div class="lb-trans"><p>Relay Therapeutics, Inc 是一家臨牀階段的生物技術公司，專注於腫瘤學的精準治療的發現和開發。公司總部位於馬薩諸塞州劍橋，成立於 2016 年，旨在利用綜合科學平台針對動態蛋白質運動。Relay Therapeutics 利用計算建模、結構生物學和實驗驗證來識別能夠調節與疾病相關的蛋白質行為的小分子藥物候選者。</p>
</div><p>The company's core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.</p>
<div class="lb-trans"><p>公司的核心業務活動集中在其專有的藥物發現引擎上，該引擎結合了高性能計算——包括分子動力學模擬——與先進的實驗技術，如冷凍電子顯微鏡和生物物理篩選。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than Relay Therapeutics</li>
<li>Strategy Inc. Buys Bitcoin and Eyes a Dividend Amid Market Fear</li>
<li>Vertical Aerospace: Pre-Flight Checks Point to a Breakout</li>
<li>Palo Alto Networks Up 70%: Can the Rally Last Into June?</li>
<li>Block’s Pivot to Profits and AI Is Turning Heads</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們認為比 Relay Therapeutics 更好的股票</li>
<li>Strategy Inc.購買比特幣並在市場恐慌中尋求分紅</li>
<li>Vertical Aerospace：飛行前檢查指向突破</li>
<li>Palo Alto Networks 上漲 70%：這波反彈能持續到 6 月嗎？</li>
<li>Block 向利潤和人工智能的轉型引起關注</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkxBWQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=RLAY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Relay Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在 Relay Therapeutics 嗎？</h2>
</div><p>Before you consider Relay Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Relay Therapeutics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Relay Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Relay Therapeutics 並不在名單上。</p>
</div><p>While Relay Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Relay Therapeutics 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Relay Therapeutics (NASDAQ:RLAY) Given New $21.00 Price Target at Citizens Jmp

Market Beat

Relay Therapeutics

醫療業 ETF - Vanguard

納斯達克生物科技指數 ETF - iShares Nasdaq

生物科技 ETF - VanEck Vectors

標普生物技術 3 倍做多 - Direxion

標普全球醫療股指數 ETF - iShares

標普生物技術 ETF - SPDR

紐交所高增長板生物技術指數 ETF - First Trust

美國制藥 ETF - iShares

基因改革 ETF - ARK

瑞銀集團

花旗

富國銀行

瑞傑金融

CITIGROUP INC 6.250 NON CUM SER II PFD WI

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

RAYMOND JAMES FINANCIAL INC 6.375%DEP SHS REP 1/40TH FXD FLTG SER B

Relay Therapeutics（納斯達克股票代碼：RLAY）被 Citizens Jmp 給予新的 21.00 美元目標價